JSB Market Research: Schizophrenia - Pipeline Review, H1 2014
This report "Schizophrenia - Pipeline Review, H1 2014'' provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
This report "Schizophrenia - Pipeline Review, H1 2014'' provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Otsuka Holdings Co., Ltd., <strong>H1</strong> <strong>2014</strong> 105<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by BIOPROJET SCR, <strong>H1</strong> <strong>2014</strong> 106<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Reviva Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 107<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Promentis Pharmaceuticals, Inc., <strong>H1</strong> <strong>2014</strong> 108<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Naurex, Inc., <strong>H1</strong> <strong>2014</strong> 109<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Acino Pharma AG, <strong>H1</strong> <strong>2014</strong> 110<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by PharmaNeuroBoost NV, <strong>H1</strong> <strong>2014</strong> 111<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by GeNeuro SA, <strong>H1</strong> <strong>2014</strong> 112<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Delpor, Inc., <strong>H1</strong> <strong>2014</strong> 113<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Mnemosyne Pharmaceuticals, Inc., <strong>H1</strong> <strong>2014</strong> 114<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Aestus Therapeutics, Inc., <strong>H1</strong> <strong>2014</strong> 115<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Rottapharm|Madaus, <strong>H1</strong> <strong>2014</strong> 116<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Sunovion Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 117<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by BioCrea GmbH, <strong>H1</strong> <strong>2014</strong> 118<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Lead Discovery Center GmbH, <strong>H1</strong> <strong>2014</strong> 119<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by BRAINco Biopharma, S.L., <strong>H1</strong> <strong>2014</strong> 120<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Echo Pharmaceuticals B.V., <strong>H1</strong> <strong>2014</strong> 121<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Cerecor Inc., <strong>H1</strong> <strong>2014</strong> 122<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Karuna Pharmaceuticals Inc., <strong>H1</strong> <strong>2014</strong> 123<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by SK Biopharmaceuticals Co., Ltd., <strong>H1</strong> <strong>2014</strong> 124<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Sage Therapeutics, <strong>H1</strong> <strong>2014</strong> 125<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by AbbVie Inc., <strong>H1</strong> <strong>2014</strong> 126<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Angita B.V., <strong>H1</strong> <strong>2014</strong> 127<br />
<strong>Schizophrenia</strong> - <strong>Pipeline</strong> by Inventiva SAS, <strong>H1</strong> <strong>2014</strong> 128<br />
Assessment by Monotherapy Products, <strong>H1</strong> <strong>2014</strong> 129<br />
Assessment by Combination Products, <strong>H1</strong> <strong>2014</strong> 130<br />
Number of Products by Stage and Target, <strong>H1</strong> <strong>2014</strong> 133<br />
Number of Products by Stage and Mechanism of Action, <strong>H1</strong> <strong>2014</strong> 139<br />
Number of Products by<br />
List of Figures<br />
Number of Products under Development for <strong>Schizophrenia</strong>, <strong>H1</strong> <strong>2014</strong> 25<br />
Number of Products under Development for <strong>Schizophrenia</strong> - Comparative Analysis, <strong>H1</strong> <strong>2014</strong> 26<br />
Number of Products under Development by Companies, <strong>H1</strong> <strong>2014</strong> 27<br />
Number of Products under Investigation by Universities/Institutes, <strong>H1</strong> <strong>2014</strong> 34<br />
Comparative Analysis by Late Stage Development, <strong>H1</strong> <strong>2014</strong> 36<br />
Comparative Analysis by Clinical Stage Development, <strong>H1</strong> <strong>2014</strong> 37<br />
Comparative Analysis by Early Stage Products, <strong>H1</strong> <strong>2014</strong> 38<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/
Change language